Immunocore Holdings plc
IMCR
$28.22
-$0.30-1.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 23.75% | 28.95% | 28.10% | 26.78% | 25.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.75% | 28.95% | 28.10% | 26.78% | 25.75% |
| Cost of Revenue | 7.27% | 9.27% | -121.62% | -97.13% | -59.69% |
| Gross Profit | 19.97% | 23.93% | 29.68% | 30.29% | 29.10% |
| SG&A Expenses | 4.07% | 6.18% | 6.58% | 3.88% | 3.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -9.29% | -9.29% | -2,112.37% | -2,112.37% | -2,112.37% |
| Total Operating Expenses | 17.74% | 17.38% | 11.33% | 8.16% | 7.55% |
| Operating Income | 50.13% | 51.11% | 60.75% | 61.94% | 59.17% |
| Income Before Tax | 47.69% | 63.92% | 47.68% | 62.22% | 65.40% |
| Income Tax Expenses | 1,465.97% | 987.24% | 116.36% | 52.25% | 79.31% |
| Earnings from Continuing Operations | -27.46% | 30.48% | 37.88% | 62.99% | 64.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.46% | 30.48% | 37.88% | 62.99% | 64.12% |
| EBIT | 50.13% | 51.11% | 60.75% | 61.94% | 59.17% |
| EBITDA | 55.40% | 53.62% | 63.84% | 65.16% | 62.62% |
| EPS Basic | -26.83% | 31.19% | 38.37% | 63.26% | 64.53% |
| Normalized Basic EPS | 43.98% | 50.40% | 45.11% | 59.78% | 63.37% |
| EPS Diluted | -26.69% | 31.47% | 38.68% | 62.84% | 64.15% |
| Normalized Diluted EPS | 42.85% | 50.67% | 45.39% | 59.25% | 62.89% |
| Average Basic Shares Outstanding | 0.87% | 0.65% | 0.69% | 0.95% | 1.49% |
| Average Diluted Shares Outstanding | -0.35% | 0.18% | 0.23% | 0.74% | 1.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |